Home › Companies › Karyopharm Therapeutics Inc. › 2025-2026
At Karyopharm Therapeutics Inc.'s 2 shareholder meetings in the 2025-2026 proxy season (held February 18, 2026 and May 21, 2026), 77 asset managers reported how they voted on 8 ballot items in their SEC Form N-PX filings, covering 280 separate fund positions. On the most widely held item of the season, voted at the meeting held May 21, 2026 — To approve, on an advisory basis, the compensation of our named executive officers, as… — Karyopharm Therapeutics Inc.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Karyopharm Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 28, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Karyopharm Therapeutics Inc.’s Form 8-K, filed May 28, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 21, 2026: 6 items on Karyopharm Therapeutics Inc.’s Form 8-K, filed May 28, 2026: 4 approved · 2 without a stated outcome.
Meeting of February 18, 2026: 2 items on Karyopharm Therapeutics Inc.’s Form 8-K, filed February 19, 2026: 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2025-2026
Explore Karyopharm Therapeutics Inc. in the interactive database Compare manager voting policies
These tallies are Karyopharm Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 28, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. Karyopharm Therapeutics Inc. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Barry E. Greene | 8,961,538 | -- | -- | 2,469,147 | 5,410,881 | 78% | Not verified | — |
| Elect Director: Christy J. Oliger | 10,601,387 | -- | -- | 829,298 | 5,410,881 | 93% | Not verified | — |
| 2. An amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended, to increase the number of shares of the Company's common stock available for issuance there under by 3,000,000 shares | 10,474,681 | 953,411 | 2,593 | -- | 5,410,881 | 92% | Approved | — |
| 3. An amendment to the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company's common stock available for issuance thereunder by 1,400,000 shares | 11,221,920 | 203,702 | 5,063 | -- | 5,410,881 | 98% | Approved | — |
| 4. The compensation of the Company's named executive officers as disclosed in the Proxy Statement | 10,025,198 | 1,388,274 | 17,213 | -- | 5,410,881 | 88% | Approved | — |
| 5. The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 16,695,588 | 86,550 | 59,428 | -- | -- | 99.4% | Approved | — |
Source: Karyopharm Therapeutics Inc., Form 8-K, filed with the SEC on May 28, 2026 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. And approved an amendment to the Company's Restated Certificate of Incorporation, as amended (the "Share Increase Amendment"), to increase the number of authorized shares of the Company's capital stock from 58,333,333 to 111,000,000 | 9,436,123 | 3,213,329 | 25,465 | -- | -- | 75% | Approved | — |
| 2. Proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of the Authorized Shares Proposa | 10,041,437 | 2,594,322 | 39,158 | -- | -- | 79% | Approved | — |
Source: Karyopharm Therapeutics Inc., Form 8-K, filed with the SEC on February 19, 2026 — read the filing on EDGAR.
Each item below shows how the 77 asset managers that disclosed a Karyopharm Therapeutics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held May 21, 2026.
Combines 5 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: To elect the following two Class I director nominees: Barry E. Greene
Karyopharm Therapeutics Inc.’s own tally for this item (“Elect Director: Barry E. Greene”): 8,961,538 for, 2,469,147 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 907,023 for, 914,097 withheld, 1,144 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 10,886 | 0 | 0 | 880,668 | Withhold |
| Vanguard | 615,880 | 0 | 1,144 | 0 | For |
| Fidelity | 166,664 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 71,873 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 33,333 | Withhold |
| Invesco | 16,738 | 0 | 0 | 0 | For |
| Charles Schwab | 13,400 | 0 | 0 | 0 | For |
| BlackRock | 9,467 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,467 | 0 | 0 | 0 | For |
| Equitable | 572 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 96 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 76 | 0 | 0 | 0 | For |
Meeting held May 21, 2026.
Combines 5 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To elect the following two Class I director nominees: Christy J. Oliger
Karyopharm Therapeutics Inc.’s own tally for this item (“Elect Director: Christy J. Oliger”): 10,601,387 for, 829,298 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 1,821,025 for, 96 withheld, 1,143 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 891,554 | 0 | 0 | 0 | For |
| Vanguard | 615,881 | 0 | 1,143 | 0 | For |
| Fidelity | 166,664 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 71,873 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 33,333 | 0 | 0 | 0 | For |
| Invesco | 16,738 | 0 | 0 | 0 | For |
| Charles Schwab | 13,400 | 0 | 0 | 0 | For |
| BlackRock | 9,467 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,467 | 0 | 0 | 0 | For |
| Equitable | 572 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 96 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 76 | 0 | 0 | 0 | For |
Meeting held February 18, 2026.
75% Approved · of votes cast
Description as filed by funds: TO ADOPT AND APPROVE AN AMENDMENT TO THE KARYOPHARM THERAPEUTICS INC. RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF OUR CAPITAL STOCK FROM 58,333,333 TO 111,000,000 AND THE NUMBER OF AUTHORIZED SHARES OF OUR COMMON STOCK FROM 53,333,333 TO 106,000,000.
Karyopharm Therapeutics Inc.’s own tally for this item (“1. And approved an amendment to the Company's Restated Certificate of Incorporation, as amended (the "Share Increase Amendment"), to increase the number of authorized shares of the Company's capital stock from 58,333,333”): 9,436,123 for, 3,213,329 against — passed, per its Form 8-K filed February 19, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 1: The Company's stockholders adopted and approved an amendment to the Company's Restated Certificate of Incorporation, as amended (the "Share Increase Amendment"), to increase the number of authorized shares of the Company's capital stock from 58,333,333 to 111,000,000”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 1,140,397 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 445,063 | 0 | 0 | 0 | For |
| T. Rowe Price | 368,054 | 0 | 0 | 0 | For |
| Fidelity | 138,610 | 0 | 0 | 0 | For |
| BlackRock | 80,814 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 65,873 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 33,333 | 0 | 0 | 0 | For |
| Charles Schwab | 3,400 | 0 | 0 | 0 | For |
| Equitable | 2,637 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,476 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,061 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 76 | 0 | 0 | 0 | For |
Meeting held February 18, 2026.
79% Approved · of votes cast
Description as filed by funds: TO APPROVE A PROPOSAL TO ADJOURN THE SPECIAL MEETING TO A LATER DATE OR DATES, IF NECESSARY TO PERMIT FURTHER SOLICITATION OF PROXIES IN THE EVENT THAT THERE ARE INSUFFICIENT VOTES FOR THE ADOPTION AND APPROVAL OF PROPOSAL 1.
Karyopharm Therapeutics Inc.’s own tally for this item (“2. A proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of the Authorized”): 10,041,437 for, 2,594,322 against — passed, per its Form 8-K filed February 19, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: The Company's stockholders approved a proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of the Authorized Shares Proposa”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 772,343 for, 368,054 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 445,063 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 368,054 | 0 | 0 | Against |
| Fidelity | 138,610 | 0 | 0 | 0 | For |
| BlackRock | 80,814 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 65,873 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 33,333 | 0 | 0 | 0 | For |
| Charles Schwab | 3,400 | 0 | 0 | 0 | For |
| Equitable | 2,637 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,476 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,061 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 76 | 0 | 0 | 0 | For |
Meeting held May 21, 2026.
Combines 2 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO THE KARYOPHARM THERAPEUTICS INC. AMENDED & RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF OUR COMMON STOCK AVAILABLE FOR ISSUANCE THEREUNDER BY 1,400,000 SHARES.
Karyopharm Therapeutics Inc.’s own tally for this item (“3. An amendment to the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company's common stock available for issuance thereunder by 1,”): 11,221,920 for, 203,702 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: The Company's stockholders approved an amendment to the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company's common stock available for issuance thereunder by 1,400,000 shares.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 891,554 | 0 | 0 | 0 | For |
| Vanguard | 617,024 | 0 | 0 | 0 | For |
| Fidelity | 166,664 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 71,873 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 33,333 | 0 | 0 | 0 | For |
| Invesco | 16,738 | 0 | 0 | 0 | For |
| Charles Schwab | 13,400 | 0 | 0 | 0 | For |
| BlackRock | 9,467 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,467 | 0 | 0 | 0 | For |
| Equitable | 572 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 96 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 76 | 0 | 0 | 0 | For |
Fund voting reports, all 12 managers: 1,822,264 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Eversept Partners, LP | 233,631 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 233,631 for.
Meeting held May 21, 2026.
92% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO THE KARYOPHARM THERAPEUTICS INC. 2022 EQUITY INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF OUR COMMON STOCK AVAILABLE FOR ISSUANCE THEREUNDER BY 3,000,000 SHARES.
Karyopharm Therapeutics Inc.’s own tally for this item (“2. An amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended, to increase the number of shares of the Company's common stock available for issuance there under by 3,000,000 shares”): 10,474,681 for, 953,411 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: The Company's stockholders approved an amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended, to increase the number of shares of the Company's common stock available for issuance there under by 3,000,000 shares.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 1,821,025 for, 1,239 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 891,554 | 0 | 0 | 0 | For |
| Vanguard | 615,881 | 1,143 | 0 | 0 | For |
| Fidelity | 166,664 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 71,873 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 33,333 | 0 | 0 | 0 | For |
| Invesco | 16,738 | 0 | 0 | 0 | For |
| Charles Schwab | 13,400 | 0 | 0 | 0 | For |
| BlackRock | 9,467 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,467 | 0 | 0 | 0 | For |
| Equitable | 572 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 96 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 76 | 0 | 0 | 0 | For |
Meeting held May 21, 2026.
Combines 8 wordings of this item as funds reported it.
88% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as described in the proxy statement.
Karyopharm Therapeutics Inc.’s own tally for this item (“4. The compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 10,025,198 for, 1,388,274 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4: The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 891,554 | 0 | 0 | 0 | For |
| Vanguard | 616,487 | 537 | 0 | 0 | For |
| Fidelity | 166,664 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 71,873 | 0 | 0 | Against |
| Delaware/Macquarie | 33,333 | 0 | 0 | 0 | For |
| Invesco | 0 | 16,738 | 0 | 0 | Against |
| Charles Schwab | 13,400 | 0 | 0 | 0 | For |
| BlackRock | 9,467 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,467 | 0 | 0 | 0 | For |
| Equitable | 572 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 96 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 76 | 0 | 0 | 0 | For |
Fund voting reports, all 12 managers: 1,733,116 for, 89,148 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1,917,354 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,770,621 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,518,472 | 0 | 0 | 0 | For |
| Catalio Capital Management, LP | 897,709 | 0 | 0 | 0 | For |
| Boxer Capital Management, LLC | 302,536 | 0 | 0 | 0 | For |
| Context Capital Management, LLC | 263,696 | 0 | 0 | 0 | For |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 233,930 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 233,631 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 188,133 | 0 | 0 | 0 | For |
| Commodore Capital LP | 169,230 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 0 | 164,587 | 0 | 0 | Against |
| BlackRock | 144,282 | 5 | 0 | 0 | For |
| Vanguard | 128,822 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 121,656 | 0 | 0 | 0 | For |
| Two Sigma | 111,278 | 0 | 0 | 0 | For |
| Goldman Sachs | 106,352 | 0 | 0 | 0 | For |
| C WorldWide Asset Management Fondsmaeglerselskab A/S | 0 | 100,000 | 0 | 0 | Against |
| ACADIAN ASSET MANAGEMENT LLC | 99,354 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 71,873 | 0 | 0 | Against |
| ADAR1 Capital Management, LLC | 70,836 | 0 | 0 | 0 | For |
| State Street | 66,800 | 0 | 0 | 0 | For |
| RBC Dominion Securities Inc. | 55,608 | 0 | 0 | 0 | For |
| Renaissance | 55,486 | 0 | 0 | 0 | For |
| Tetragon Partners GP Ltd | 52,984 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 46,951 | 0 | 0 | 0 | For |
Institutional-manager reports, all 68 managers: 8,761,997 for, 451,401 against. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held May 21, 2026.
99.4% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.
Karyopharm Therapeutics Inc.’s own tally for this item (“5. The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 16,695,588 for, 86,550 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 5: The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 1,822,264 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 891,554 | 0 | 0 | 0 | For |
| Vanguard | 617,024 | 0 | 0 | 0 | For |
| Fidelity | 166,664 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 71,873 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 33,333 | 0 | 0 | 0 | For |
| Invesco | 16,738 | 0 | 0 | 0 | For |
| Charles Schwab | 13,400 | 0 | 0 | 0 | For |
| BlackRock | 9,467 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,467 | 0 | 0 | 0 | For |
| Equitable | 572 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 96 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 76 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 22,662,943 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 3.93% |
| 2 | Vanguard | 2.72% |
| 3 | Fidelity | 0.74% |
| 4 | BRIDGEWAY FUNDS INC | 0.32% |
| 5 | Delaware/Macquarie | 0.15% |
| 6 | Invesco | 0.07% |
| 7 | Charles Schwab | 0.06% |
| 8 | BlackRock | 0.04% |
| 9 | Blackstone Alternative Investment Funds | <0.01% |
| 10 | Equitable | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 8.46% |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.81% |
| 3 | T. Rowe Price | 6.70% |
| 4 | Catalio Capital Management, LP | 3.96% |
| 5 | Boxer Capital Management, LLC | 1.33% |
| 6 | Context Capital Management, LLC | 1.16% |
| 7 | DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 1.03% |
| 8 | Eversept Partners, LP | 1.03% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 0.83% |
| 10 | Commodore Capital LP | 0.75% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | 10.16% | 13G |
| Affinity Asset Advisors, LLC | 9.15% | 13G |
| Commodore Capital LP | 8.60% | DEF14A |
| Affinity Healthcare Fund, LP | 7.56% | DEF14A |
| T. Rowe Price Investment Management, Inc. | 6.79% | 13G |
| Adage Capital Management, L.P. | 6.78% | 13G |
| Anders Hove | 4.51% | 13G |
| Goldman Sachs | 4.18% | 13F |
| Opaleye Management Inc. | 2.73% | 13G |
| Vanguard Group | 2.47% | 13F |
Percentages above are of 22,662,943 shares outstanding, as reported by Karyopharm Therapeutics Inc. on its Form 10-Q dated May 7, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Karyopharm Therapeutics Inc.’s 10-Q dated May 7, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Karyopharm Therapeutics Inc. proxy season coverage: 2023-2024 · 2025-2026 (this page).
proxyvotesnow.com, “Karyopharm Therapeutics (KPTI) 2026 Annual & Special Meetings”, https://proxyvotesnow.com/company/karyopharm-therapeutics-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.